Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: Silo Pharma Inc. SILO

MissionIRNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Working to Deliver Novel Treatment for Chronic Pain Sufferers

Posted on June 23, 2023 by MissionIR

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, recently announced a new research and development agreement to create a time-release ketamine implant to treat fibromyalgia and other chronic pain conditions. Silo … Continue reading →

Posted in Silo Pharma Inc. SILO | Leave a comment

MissionIRNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Secures US Patent for SPU-21 Treatment for Autoimmune Disease

Posted on June 21, 2023 by MissionIR

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (“USPTO”) has issued U.S. Patent 16/825,371 titled “Peptide-Targeted Liposomal Delivery for Treatment, Diagnosis and … Continue reading →

Posted in Silo Pharma Inc. SILO | Leave a comment

MissionIRNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease

Posted on May 9, 2023 by MissionIR

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has received a patent from the U.S. Patent and Trademark Office (“USPTO”). Titled “Biomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders,” … Continue reading →

Posted in Silo Pharma Inc. SILO | Leave a comment

Silo Pharma Inc. (NASDAQ: SILO) Provides Update on Innovative Study Looking into the Feasibility of Using Ketamine Formulations as an Alternative Treatment for Fibromyalgia

Posted on March 28, 2023 by MissionIR

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused around merging traditional therapeutics with psychedelic research, recently announced that it had achieved a positive outcome for its toxicology study of SP-26, its novel time-released, dosage-controlled formulation of ketamine. The … Continue reading →

Posted in Silo Pharma Inc. SILO | Leave a comment

MissionIRNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Patent for Treatment of Fibromyalgia

Posted on March 27, 2023 by MissionIR

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has filed a provisional patent application titled “Methods and Compositions for Pain Management.” The methods and compositions described in … Continue reading →

Posted in Silo Pharma Inc. SILO | Leave a comment

MissionIRNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Positioned as Frontrunner in Psychedelic Drugs Market

Posted on March 24, 2023 by MissionIR

Silo Pharma (NASDAQ: SILO) is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. “Silo Pharma has distinguished itself amongst peers for its ground-breaking research into conditions such as post-traumatic stress disorder (‘PTSD’), fibromyalgia, Alzheimer’s disease, and … Continue reading →

Posted in Silo Pharma Inc. SILO | Leave a comment

MissionIRNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Positive Results from IND-Enabling Toxicology Study of SP-26

Posted on March 15, 2023 by MissionIR

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has achieved positive results for its toxicology study of SP-26, its novel time-released, dosage-controlled formulation of ketamine. In collaboration … Continue reading →

Posted in Silo Pharma Inc. SILO | Leave a comment

Silo Pharma Inc. (NASDAQ: SILO) Set to Benefit as Study Supports the Efficacy of Psychedelics in Treating ‘Drug-Resistant’ Depression

Posted on March 13, 2023 by MissionIR

In a study carried out between 2013 to 2016, researchers found that 8.1% of American adults aged 20 and over suffered from depression during any given 2-week period, with women nearly twice as likely than men to have had acute … Continue reading →

Posted in Silo Pharma Inc. SILO | Leave a comment

MissionIRNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Expands Intellectual Property, Technology Rights for Treating Rare Stress-Related Medical Conditions

Posted on March 3, 2023 by MissionIR

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, was recently issued U.S. Patent 11,491,120 for SPC-15 formulation by the U.S. Patent and Trademark Office (“USPTO”). “The patent, titled ‘Pharmacological Prophylactics Against … Continue reading →

Posted in Silo Pharma Inc. SILO | Leave a comment

Silo Pharma Inc. (NASDAQ: SILO) Granted US Patent For SPC-15 to Prevent and Treat Stress-Induced Disorders

Posted on February 22, 2023 by MissionIR

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, was recently issued US Patent 11,491,120 by the US Patent and Trademark Office (“USPTO”) (https://ibn.fm/rMLOR). The patent, titled “Pharmacological Prophylactics Against Stress-Induced Affective … Continue reading →

Posted in Silo Pharma Inc. SILO | Leave a comment